Daniel is an expert in epigenetic T-cell modulation. Founder and CMO of Rapa Therapeutics, which is developing rapamycin-reprogrammed T-cells for cancer and autoimmune targeting. He is developing the use of RAPA-501 cells to target ALS, which are manufactured ex-vivo to attain dual TREG/Th2 anti-inflammatory activity and a T-stem phenotype that permits T cell therapy without conditioning chemotherapy.